Lacrimal Gland Tumors

  • David H. Verity
  • Geoffrey E. RoseEmail author


While 9–15% of orbital tumors arise in lacrimal gland, inflammatory or infiltrative diseases – such as sarcoidosis, Wegener’s granulomatosis, IgG4 disease, or other (nonspecific) dacryoadenitis – comprise two-thirds of lacrimal gland masses and can present with signs and symptoms similar to tumors. Often a firm diagnosis can be reached only with tissue biopsy.


Lacrimal Gland Tumor Pleomorphic adenoma Adenoid cystic carcinoma Malignant mixed tumor Adenocarcinoma Genetics 


  1. 1.
    Shields JA, Shields CL, Epstein JA, et al. Primary epithelial malignancies of the lacrimal gland: the 2003 Ramon L. Font Lecture. Ophthalmic Plast Reconstr J. 2004;20:10–21.Google Scholar
  2. 2.
    Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: the 2002 Montgomery Lecture, part 1. Ophthalmology. 2004;111:997–1008.PubMedGoogle Scholar
  3. 3.
    Jenkins C, Rose GE, Bunce C, et al. Clinical features associated with survival of patients with lymphoma of the ocular adnexa. Eye. 2003;17:809–20.PubMedGoogle Scholar
  4. 4.
    Rose GE, Wright JE. Pleomorphic adenoma of the lacrimal gland. Br J Ophthalmol. 1992;76:395–400.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Wright JE, Rose GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol. 1992;76:401–7.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Rootman J, White V, Hind A. Tumors of the lacrimal gland. In: Rootman J, editor. Disease of the orbit. A multidisciplinary approach. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.Google Scholar
  7. 7.
    Cates CA, Manners RM, Rose GE. Pleomorphic adenoma of the lacrimal gland in a 10 year old girl. Br J Ophthalmol. 2002;86:249–50.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Vangveeravong S, Katz SE, Rootman J, White V. Tumors arising in the palpebral lobe of the lacrimal gland. Ophthalmology. 1996;103:1606–12.PubMedGoogle Scholar
  9. 9.
    Lorenzano D, Rose GE. The “wedge sign”: an imaging sign for aggressive lacrimal gland disease. Ophthalmology. 2017;124:1081–3.PubMedGoogle Scholar
  10. 10.
    Aviv RI, Miszkiel K. Orbital imaging: part 2. Intraorbital pathology. Clin Radiol. 2005;60:288–307.PubMedGoogle Scholar
  11. 11.
    Rose GE. To crash or not to crash? Probability in the management of benign lacrimal gland tumours. Eye. 2009;23:1625–8.PubMedGoogle Scholar
  12. 12.
    Prabhakaran VC, Cannon PS, McNab A, et al. Lesions mimicking lacrimal gland pleomorphic adenoma. Br J Ophthalmol. 2010;94:1509–12.PubMedGoogle Scholar
  13. 13.
    Kopp ED, Sahlin S, Tani E, et al. Fine- needle aspiration biopsy in lacrimal gland pleomorphic adenoma. Eye. 2010;24:386–9.PubMedGoogle Scholar
  14. 14.
    Perzin KH, Jakobiec FA, Livolsi VA, et al. Lacrimal gland malignant mixed tumors (carcinomas arising in benign mixed tumors): a clinico-pathologic study. Cancer. 1980;45:2593–606.PubMedGoogle Scholar
  15. 15.
    Kim YJ, Kim YS, Chin S, et al. Cytoplasmic and nuclear leptin expression in lacrimal gland tumours: a pilot study. Br J Ophthalmol. 2015;99:1306–10.PubMedGoogle Scholar
  16. 16.
    Currie ZI, Rose GE. Long-term risk of recurrence after intact excision of pleomorphic adenomas of the lacrimal gland. Arch Ophthalmol. 2007;125:1643–6.PubMedGoogle Scholar
  17. 17.
    Ni C, Kuo PK, Dryja TP. Histopathological classification of 272 primary epithelial tumors of the lacrimal gland. Chin Med J. 1992;105:481–5.PubMedGoogle Scholar
  18. 18.
    Rose GE, Wright JE. Exenteration for benign orbital disease. Br J Ophthalmol. 1994;78:14–8.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Polito E, Leccisotti A. Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy. Ann Ophthalmol. 1993;25:422–6.PubMedGoogle Scholar
  20. 20.
    Ahmad SM, Esmaeli B, Williams M, et al. American Joint Committee on Cancer classification predicts outcome of patients with lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2009;116:1210–5.PubMedGoogle Scholar
  21. 21.
    Skinner HD, Garden AS, Rosenthal DI, et al. Outcomes of malignant tumors of the lacrimal apparatus. Cancer. 2011;117:2801–10.PubMedGoogle Scholar
  22. 22.
    Esmaeli B, Yin V, Hanna E, et al. Eye-sparing multidisciplinary approach for the management of lacrimal gland carcinoma. Head Neck. 2014;38:1258–62.Google Scholar
  23. 23.
    Woo KI, Kim YD, Sa HS, et al. Current treatment of lacrimal gland carcinoma. Curr Opin Ophthalmol. 2016;27:449–56.PubMedGoogle Scholar
  24. 24.
    Han J, Kim YD, Woo KI, et al. Long-term outcomes of eye-sparing surgery for adenoid cystic carcinoma of lacrimal gland. Ophthal Plast Reconstr Surg. 2018;34:74–8.PubMedGoogle Scholar
  25. 25.
    Woo KI, Sagiv O, Han J, et al. Eye-preserving surgery followed by adjuvant radiotherapy for lacrimal gland carcinoma: outcomes in 37 patients. Ophthal Plast Reconstr Surg. 2018;34(6):570–4.PubMedGoogle Scholar
  26. 26.
    Gore SK, Plowman NP, Dharmasena A, et al. Corneal complications after orbital radiotherapy for primary epithelial malignancies of the lacrimal gland. Br J Ophthalmol. 2018;102(7):882–4.PubMedGoogle Scholar
  27. 27.
    Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116:315–21.PubMedGoogle Scholar
  28. 28.
    Tse DT, Benedetto P, Dubovy S, et al. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141:44–53.PubMedGoogle Scholar
  29. 29.
    Tse DT, Kossler AL, Feuer WJ, et al. Long-term outcomes of neoadjuvant intraarterial cytoreductive chemotherapy for lacrimal gland adenoid cystic carcinoma. Ophthalmology. 2013;120:1313–23.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Le Tourneau C, Razak ARA, Levy C, et al. Role of chemotherapy and molecularly targeted agents in the treatment of adenoid cystic carcinoma of the lacrimal gland. Br J Ophthalmol. 2011;95:1483–9.PubMedGoogle Scholar
  31. 31.
    Esmaeli B, Ahmadi MA, Youssef A, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthal Plast Reconstr Surg. 2004;20:22–6.PubMedGoogle Scholar
  32. 32.
    Heaps RS, Miller NR, Albert DM, et al. Primary adenocarcinoma of the lacrimal gland. A retrospective study. Ophthalmology. 1993;100:1856–60.PubMedGoogle Scholar
  33. 33.
    Font RL, Gamel JW. Epithelial tumors of the lacrimal gland: an analysis of 265 cases. In: Jakobiec FA, editor. Ocular and adnexal tumors. Birmingham: Aesculapius; 1978. p. 787–805.Google Scholar
  34. 34.
    El-Sawy T, Savar A, Williams MD, et al. Prognostic accuracy of the seventh edition vs sixth edition of the American Joint Committee on cancer tumor classification for adenoid cystic carcinoma of the lacrimal gland. Arch Ophthalmol. 2012;130:664–6.PubMedGoogle Scholar
  35. 35.
    Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000;84:907–13.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Tse D. Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Trans Am Ophthalmol Soc. 2005;103:337–67.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Bell D, Sniegowski MC, Wani K, et al. Mutational landscape of lacrimal gland carcinomas and implications for treatment. Head Neck. 2016;38:E724–9.PubMedGoogle Scholar
  38. 38.
    Sant DW, Tao W, Field MG, et al. Whole exome sequencing of lacrimal gland adenoid cystic carcinoma. Invest Ophthalmol Vis Sci. 2017;58:BIO240–6.PubMedPubMedCentralGoogle Scholar
  39. 39.
    von Holstein SL, Fehr A, Persson M, et al. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120:2130–8.Google Scholar
  40. 40.
    Chen TY, Keeney MG, Chintakuntlawar AV, et al. Adenoid cystic carcinoma of the lacrimal gland is frequently characterized by MYB rearrangement. Eye (Lond). 2017;31:720–5.Google Scholar
  41. 41.
    Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci. 2009;106:18740–4.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Adnexal ServiceMoorfields Eye HospitalLondonUK
  2. 2.NIHR Biomedical CentreInstitute of OphthalmologyLondonUK

Personalised recommendations